Rep. Maria Elvira Salazar Purchases Shares of Amgen Inc. (NASDAQ:AMGN)

Representative Maria Elvira Salazar (Republican-Florida) recently bought shares of Amgen Inc. (NASDAQ:AMGN). In a filing disclosed on April 21st, the Representative disclosed that they had bought between $15,001 and $50,000 in Amgen stock on March 24th. The trade occurred in the Representative’s “UBS IRA ACCOUNT” account.

Representative Maria Elvira Salazar also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of United Rentals (NYSE:URI) on 3/25/2026.
• Purchased $1,001 – $15,000 in shares of FedEx (NYSE:FDX) on 3/25/2026.
• Purchased $15,001 – $50,000 in shares of Honeywell International (NASDAQ:HON) on 3/24/2026.
• Purchased $1,001 – $15,000 in shares of GE Aerospace (NYSE:GE) on 3/24/2026.
• Purchased $15,001 – $50,000 in shares of Boeing (NYSE:BA) on 3/19/2026.
• Purchased $1,001 – $15,000 in shares of Cisco Systems (NASDAQ:CSCO) on 3/19/2026.
• Purchased $15,001 – $50,000 in shares of Cisco Systems (NASDAQ:CSCO) on 3/19/2026.
• Purchased $15,001 – $50,000 in shares of FedEx (NYSE:FDX) on 3/19/2026.
• Purchased $15,001 – $50,000 in shares of The Goldman Sachs Group (NYSE:GS) on 3/19/2026.
• Purchased $15,001 – $50,000 in shares of Ulta Beauty (NASDAQ:ULTA) on 3/19/2026.

Amgen Trading Up 0.3%

Shares of AMGN opened at $345.92 on Thursday. The stock has a market capitalization of $186.69 billion, a P/E ratio of 24.31, a PEG ratio of 3.61 and a beta of 0.47. Amgen Inc. has a twelve month low of $261.43 and a twelve month high of $391.29. The company has a quick ratio of 0.90, a current ratio of 1.14 and a debt-to-equity ratio of 5.78. The firm has a fifty day simple moving average of $361.59 and a two-hundred day simple moving average of $338.73.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.76 by $0.53. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The company had revenue of $9.87 billion for the quarter, compared to analysts’ expectations of $9.46 billion. During the same period last year, the firm earned $5.31 earnings per share. Amgen’s quarterly revenue was up 8.6% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, research analysts anticipate that Amgen Inc. will post 22.18 EPS for the current year.

Amgen Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be given a dividend of $2.52 per share. The ex-dividend date of this dividend is Friday, May 15th. This represents a $10.08 annualized dividend and a yield of 2.9%. Amgen’s dividend payout ratio is presently 70.84%.

Hedge Funds Weigh In On Amgen

Large investors have recently modified their holdings of the stock. Brighton Jones LLC raised its stake in shares of Amgen by 23.5% in the fourth quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock worth $7,159,000 after purchasing an additional 5,226 shares during the last quarter. Sivia Capital Partners LLC raised its stake in Amgen by 10.6% during the 2nd quarter. Sivia Capital Partners LLC now owns 1,186 shares of the medical research company’s stock valued at $331,000 after buying an additional 114 shares during the last quarter. Schnieders Capital Management LLC. boosted its stake in shares of Amgen by 29.3% in the 2nd quarter. Schnieders Capital Management LLC. now owns 25,859 shares of the medical research company’s stock worth $7,220,000 after buying an additional 5,853 shares during the last quarter. Main Street Financial Solutions LLC increased its position in Amgen by 11.3% during the second quarter. Main Street Financial Solutions LLC now owns 4,086 shares of the medical research company’s stock valued at $1,141,000 after acquiring an additional 416 shares during the last quarter. Finally, Ieq Capital LLC grew its stake in shares of Amgen by 5.1% during the 2nd quarter. Ieq Capital LLC now owns 54,152 shares of the medical research company’s stock valued at $15,120,000 after purchasing an additional 2,611 shares during the period. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently commented on the company. Canaccord Genuity Group started coverage on Amgen in a research note on Monday. They issued a “hold” rating and a $366.00 price target for the company. The Goldman Sachs Group upped their price objective on shares of Amgen from $403.00 to $415.00 and gave the stock a “buy” rating in a report on Wednesday, February 4th. Rothschild & Co Redburn boosted their price target on shares of Amgen from $180.00 to $200.00 and gave the company a “sell” rating in a research report on Wednesday, February 18th. Morgan Stanley raised their price objective on shares of Amgen from $309.00 to $326.00 and gave the stock an “equal weight” rating in a report on Friday, April 10th. Finally, UBS Group raised their target price on Amgen from $390.00 to $400.00 and gave the company a “buy” rating in a research note on Monday, April 13th. One research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, fourteen have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, Amgen presently has an average rating of “Hold” and an average price target of $356.62.

Key Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Guggenheim nudged its price target up to $351 (from $347) ahead of earnings, citing an updated model — a modest upgrade that supports the stock’s near-term upside. Guggenheim Adjusts Amgen Inc. (AMGN) PT to $351, Cites Updated Model Ahead of Earnings
• Positive Sentiment: Increased retail/investor attention reported by Zacks highlights AMGN as a “trending” stock — that can boost flows and short-term liquidity. Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It
• Neutral Sentiment: Amgen announced the retirement of CTO David M. Reese (effective June 30) and said it will realign leadership to integrate biology and technology — a purposeful transition but without immediate operational red flags. AMGEN ANNOUNCES RETIREMENT OF DAVID M. REESE, EXECUTIVE VICE PRESIDENT AND CHIEF TECHNOLOGY OFFICER
• Neutral Sentiment: Canaccord Genuity initiated coverage with a Hold recommendation — indicates cautious analyst stance but not a downgrade signal. Canaccord Genuity initiates coverage of Amgen (AMGN) with hold recommendation
• Neutral Sentiment: Bernstein issued a Hold on AMGN, echoing a cautious consensus among some sell-side analysts despite Amgen’s solid fundamentals. Amgen (AMGN) Receives a Hold from Bernstein
• Negative Sentiment: Multiple insiders sold about US$4.1M of AMGN stock over the past year — a signal some investors view as caution from management-level holders. Amgen Insiders Sell US$4.1m Of Stock, Possibly Signalling Caution

About Representative Salazar

Maria Elvira Salazar (Republican Party) is a member of the U.S. House, representing Florida’s 27th Congressional District. She assumed office on January 3, 2021. Her current term ends on January 3, 2027.

Salazar (Republican Party) ran for re-election to the U.S. House to represent Florida’s 27th Congressional District. She won in the general election on November 5, 2024.

Maria Elvira Salazar was born in Miami, Florida, and lives in Coral Gables, Florida. Salazar earned an undergraduate degree from the University of Miami in 1983 and a graduate degree from Harvard University in 1995. Her career experience includes working as a television journalist, reporter, and news anchor.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.